Bayer hit with $332 million judgement in trial of man who blames his cancer on decades using Monsanto’s Roundup weedkiller

Farmers Matt Wiggeim, right, and Cody Gibson mix Monsanto's Roundup herbicide near a corn field in Kasbeer, Ill., U.S., on June 13, 2011.
Farmers Matt Wiggeim, right, and Cody Gibson mix Monsanto's Roundup herbicide near a corn field in Kasbeer, Ill., U.S., on June 13, 2011.
Daniel Acker—Bloomberg via Getty Images

A California jury has awarded $332 million to a man who sued chemical giant Monsanto Co. contending that his cancer was related to decades of using its Roundup weedkiller.

A San Diego Superior Court jury awarded damages Tuesday in a lawsuit filed by Mike Dennis, 57, of Carlsbad. He was diagnosed in 2020 with a rare form of non-Hodgkin’s lymphoma.

His lawsuit contended that his illness was related to Roundup’s active ingredient, glyphosate.

Dennis had treatment and has been in remission for nearly three years but there is no cure, Adam Peavy, one of his attorneys, told KNSD-TV.

“His doctors have told him it’s going to come back and we’re just waiting to see if that happens,” Peavy said.

The jury found that Monsanto, which is now a division of pharmaceutical and biotechnology giant Bayer, failed to provide warnings of Roundup’s risks. But jurors also ruled partially in Bayer’s favor by finding the product design wasn’t defective and the company wasn’t negligent.

Dennis was awarded $7 million in compensatory damages and $325 million in punitive damages.

In a statement to KNSD-TV, Bayer said it believes “we have strong arguments on appeal to get this unfounded verdict overturned and the unconstitutionally excessive damage award eliminated or reduced.”

“There were significant and reversible legal and evidentiary errors made during this trial,” Bayer added.

Bayer bought Monsanto for $63 billion in 2018 and has been trying to deal with thousands of claims and lawsuits related to Roundup. In 2020, Bayer announced it would pay up to $10.9 billion to settle some 125,000 filed and unfiled claims.

Subscribe to the CFO Daily newsletter to keep up with the trends, issues, and executives shaping corporate finance. Sign up for free.